Actively Recruiting
Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
Led by Royal Marsden NHS Foundation Trust · Updated on 2026-03-12
200
Participants Needed
1
Research Sites
735 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
FORTITUDE is a translational research study that aims to collect serial multi-site needle biopsy samples of tumour tissue and blood from metastatic breast cancer patients. Cancer biopsies are generally performed when cancer is diagnosed and are sometimes repeated when the cancer is suspected to have spread but this is not mandatory. However, studies have shown that cancers change with time and evolve to become resistant to therapy. The purpose of this study is to assess the feasibility of biopsies of multiple cancer sites across different time points during treatment and understand how cancers evolve and change throughout treatment. The findings of this study could pave the way for using cancer biopsies more frequently in the clinic to pick up changes in cancer behaviour that could influence treatment choice. The samples collected from this study will be used for molecular and genetic research to increase our understanding of how metastatic breast cancer changes during treatment and will enable us to develop new cancer treatments and new ways of monitoring response to cancer therapies.
CONDITIONS
Official Title
Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed locally advanced, inoperable breast cancer or metastatic breast cancer OR radiological evidence of metastatic disease strongly suspected to be recurrence of previously diagnosed breast cancer
- Age 18 years or older
- Provided written informed consent to participate
You will not qualify if you...
- Metastatic disease limited only to bones without any soft tissue involvement
- Bleeding disorders or anticoagulation that cannot be corrected making biopsy risk unacceptable
- Significant biopsy risk greater than 1% as assessed by physician
- Eastern Cooperative Oncology Group performance status of 3 or higher
- Known chronic infectious diseases such as Hepatitis B, Hepatitis C, or HIV that may affect safety
- Psychological, familial, or social conditions that may interfere with study compliance and follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Royal Marsden NHS Foundation Trust
London, United Kingdom, SW3 6JJ
Actively Recruiting
Research Team
S
Sophie Cooke
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here